Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18560527 | 1.00 | GLP1R (0.54) | GLP1RITGB3ITGA2BTP53TSHR | |
| SCHEMBL21242883 | 0.97 | GLP1R (0.58) | GLP1RITGB3ITGA2BTP53TSHR | |
| SCHEMBL12501585 | 0.95 | GLP1R (0.56) | GLP1RITGB3ITGA2BTP53TSHR | |
| SCHEMBL15359862 | 0.93 | GLP1R (0.64) | GLP1RITGB3ITGA2BTP53TSHR | |
| SCHEMBL24652677 | 0.93 | GLP1R (0.59) | GLP1RITGB3ITGA2BTP53TSHR | |
| SCHEMBL12497136 | 0.93 | GLP1R (0.59) | GLP1RITGB3ITGA2BTP53TSHR | |
| SCHEMBL12501560 | 0.93 | GLP1R (0.59) | GLP1RITGB3ITGA2BTP53TSHR | |
| SCHEMBL20652754 | 0.93 | GLP1R (0.63) | GLP1RITGB3ITGA2BTP53TSHR | |
| SCHEMBL12496921 | 0.93 | GLP1R (0.59) | GLP1RITGB3ITGA2BTP53TSHR | |
| SCHEMBL12496872 | 0.93 | GLP1R (0.59) | GLP1RITGB3ITGA2BTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| EP-2513141-B1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-01 | — | — | EP | claimed |
| EP-2513140-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2015-11-04 | — | — | EP | claimed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | disclosed |
| EP-3000482-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2021-04-21 | — | — | EP | disclosed |
| EP-2513141-B1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-01 | — | — | EP | disclosed |
| EP-3000482-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2016-03-30 | — | — | EP | disclosed |
| EP-2513140-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2015-11-04 | — | — | EP | disclosed |
| US-8815802-B2 | GLP-1 analogues and derivatives | NOVO NORDISK A/S (DK) | 2014-08-26 | — | — | US | disclosed |
| EP-2637698-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2013-09-18 | — | — | EP | disclosed |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| EP-2513141-A2 | GLP-1 ANALOGUES AND DERIVATIVES | Novo Nordisk A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| EP-2513140-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012062803-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011080102-A2 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011080103-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | GLP1R, IAPP, SLC5A1 | GLP1R 1/4885ITGB3 4329/4885ITGA2B 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.